Tag Archive for: CSO

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform   Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer […]

AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer

Munich, 17 October, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO). Gudrun will be responsible for AMSilk’s protein and strain strategy as well as bridging science and business development. With many years of experience in biotechnology research, Gudrun has a […]

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of […]